Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Xilio Therapeutics, Inc. XLO
$3.20
+$0.01 (0.16%)
На 18:05, 12 мая 2023
+118.75%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
87630895.00000000
-
week52high
4.92
-
week52low
1.95
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-3.04000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 мар 2023 г. в 21:05
Описание компании
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 10 авг 2022 г. |
| HC Wainwright & Co. | Buy | 10 янв 2022 г. | |
| Raymond James | Outperform | 16 ноя 2021 г. | |
| Morgan Stanley | Overweight | 16 ноя 2021 г. | |
| Cowen & Co. | Outperform | 16 ноя 2021 г. | |
| Raymond James | Outperform | Outperform | 10 ноя 2022 г. |
| Chardan Capital | Buy | 21 дек 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| English Edward C | A | 24000 | 24000 | 01 янв 2023 г. |
| Huber Martin H. Jr. | A | 136500 | 136500 | 01 янв 2023 г. |
| Russo Rene | A | 350000 | 350000 | 01 янв 2023 г. |
| Heyman Tomas J. | A | 26400 | 26400 | 15 сент 2022 г. |
| Huber Martin H. Jr. | A | 20000 | 20000 | 15 июн 2022 г. |
| Bonstein Sara | A | 13200 | 13200 | 15 июн 2022 г. |
| Xu Yuan | A | 13200 | 13200 | 15 июн 2022 г. |
| Clancy Paul J | A | 13200 | 13200 | 15 июн 2022 г. |
| Rossi Christina | A | 13200 | 13200 | 15 июн 2022 г. |
| Ross Michael Jay | A | 13200 | 13200 | 15 июн 2022 г. |
Новостная лента
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
GlobeNewsWire
02 февр 2023 г. в 07:30
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023, at 3:55 p.m. ET in New York.
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next' Summit
GlobeNewsWire
04 ноя 2022 г. в 07:30
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET.
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
GlobeNewsWire
22 сент 2022 г. в 16:05
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET.
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
GlobeNewsWire
06 сент 2022 г. в 16:05
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate virtually in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 2:55 p.m. ET.
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
GlobeNewsWire
18 мая 2022 г. в 07:30
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 2:30 p.m. ET.